Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) have been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $30.62.

Several research analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a research report on Friday, February 21st. Canaccord Genuity Group raised their price target on Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Evercore ISI raised their price target on Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Scotiabank raised their price target on Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 12th. Finally, HC Wainwright raised their price target on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, SVP William E. Rote sold 5,200 shares of Travere Therapeutics stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total transaction of $122,356.00. Following the completion of the sale, the senior vice president now directly owns 98,519 shares of the company’s stock, valued at $2,318,152.07. The trade was a 5.01 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Sandra Calvin sold 54,244 shares of Travere Therapeutics stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.00. Following the sale, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at $1,360,250. This trade represents a 49.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 206,335 shares of company stock worth $4,453,012. Company insiders own 3.75% of the company’s stock.

Institutional Trading of Travere Therapeutics

A number of institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System lifted its holdings in Travere Therapeutics by 10.8% during the 4th quarter. California State Teachers Retirement System now owns 72,192 shares of the company’s stock worth $1,258,000 after buying an additional 7,041 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Travere Therapeutics during the fourth quarter worth about $4,418,000. GF Fund Management CO. LTD. acquired a new stake in shares of Travere Therapeutics during the fourth quarter worth about $31,000. Public Employees Retirement System of Ohio increased its position in shares of Travere Therapeutics by 102.0% during the fourth quarter. Public Employees Retirement System of Ohio now owns 102,756 shares of the company’s stock worth $1,790,000 after purchasing an additional 51,876 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its position in shares of Travere Therapeutics by 33.6% during the fourth quarter. Voloridge Investment Management LLC now owns 1,007,197 shares of the company’s stock worth $17,545,000 after purchasing an additional 253,402 shares in the last quarter.

Travere Therapeutics Price Performance

TVTX stock opened at $20.53 on Friday. The business has a fifty day moving average of $20.50 and a two-hundred day moving average of $18.10. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -5.01 and a beta of 0.75. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The business had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. As a group, research analysts anticipate that Travere Therapeutics will post -1.4 earnings per share for the current year.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.